This is a competitive renewal application to continue the study of mechanisms of vaccine efficacy against Streptococcus pneumoniae. Pneumococcal disease remains a cause of significant mortality and morbidity in patients with HIV infection, particularly in regions where HAART is not available, and could re-emerge as a major problem in those receiving HAART as they reach senescence. The importance of understanding mechanisms of vaccine efficacy against pneumococcus is heightened by the prevalence of drug-resistant isolates and concerns about the efficacy of licensed vaccines in immunocompromised adults and serotype replacement in vaccinated children. Available knowledge cannot predict whether vaccine-induced immune responses will be protective or the individuals who will be protected by vaccination. In the prior funding period my research program made the observation that although it did not promote opsonophagocytosis in vitro, the efficacy of a protective serotype-specific IgM was associated with modulation of the proinflammatory cytokine response to experimental pneumococcal challenge in mice. These findings challenged the current paradigm that links vaccine efficacy to opsonic antibody. The focus of this competing renewal application is on the antibody characteristics and host variables that govern vaccine efficacy against pneumococcal bacteremia and pneumonia. Our central hypothesis is that certain serotype-specific antibodies mediate protection by modulating the host inflammatory response to pneumococcal infection. We propose to validate or refute this hypothesis in mouse strains with defined cellular immune defects, which will allow us to precisely define the contributions of T and B cells to vaccine efficacy.
Three Specific Aims are proposed: 1) To identify components of innate and cellular immunity required for vaccine efficacy against pneumococcal bacteremia and pneumonia; 2) To assemble a mechanistic framework of vaccine efficacy based on the nature of the Ab response and immune response of the host; and 3) To identify mechanisms of Ab efficacy against bacteremia and pneumonia and determine their dependency on the nature of the Ab and immune status of the host. We anticipate that the studies proposed herein will provide important new knowledge about the protective immune response to S. pneumoniae that will translate into identification of new correlates of vaccine efficacy and the generation of hypotheses for future testing in human studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI045459-08
Application #
7340438
Study Section
AIDS-associated Opportunistic Infections and Cancer Study Section (AOIC)
Program Officer
Lambros, Chris
Project Start
2000-07-01
Project End
2011-01-31
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
8
Fiscal Year
2008
Total Cost
$395,309
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Rodriguez-Barradas, Maria C; Serpa, Jose A; Munjal, Iona et al. (2015) Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial. J Infect Dis 211:1703-11
Rohatgi, Soma; Gohil, Shruti; Kuniholm, Mark H et al. (2013) Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease. MBio 4:e00573-13
Vernatter, Joshua; Pirofski, Liise-anne (2013) Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 26:277-83
Szymczak, Wendy A; Sellers, Rani S; Pirofski, Liise-anne (2012) IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms. Am J Pathol 180:1547-59
Weber, Sarah; Tian, Haijun; van Rooijen, Nico et al. (2012) A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fc? receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect Immun 80:1314-22
Hofmeyer, Kimberly A; Scandiuzzi, Lisa; Ghosh, Kaya et al. (2012) Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. J Immunol 189:3054-63
Casadevall, Arturo; Pirofski, Liise-Anne (2012) Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. Cell Host Microbe 11:447-56
Gohil, Shruti K; Heo, Moonseong; Schoenbaum, Ellie E et al. (2012) CD8+ T cells and risk for bacterial pneumonia and all-cause mortality among HIV-infected women. J Acquir Immune Defic Syndr 60:191-8
Yano, Masahide; Gohil, Shruti; Coleman, J Robert et al. (2011) Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. MBio 2:
Seyoum, Beza; Yano, Masahide; Pirofski, Liise-anne (2011) The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response. Vaccine 29:8002-11

Showing the most recent 10 out of 52 publications